The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Summary

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Solid Tumor
• Advanced Malignant Neoplasm
• Metastatic Cancer
• Metastatic Solid Tumor
• Lung Cancer
• Ovarian Cancer
• Endometrial Cancer
• Prostate Cancer
• Colorectal Cancer
• Breast Cancer
• Other Cancer
• Locally Advanced
• Head and Neck Cancer
• Gall Bladder Cancer
• Small Cell Lung Cancer
• Small Cell Lung Cancer ( SCLC )
• Small Cell Lung Carcinoma
• NSCLC
• NSCLC (Non-small Cell Lung Cancer)
• SCLC
• Non-Small Cell Lung Carcinoma
• Triple Negative Breast Cancer
• TNBC
• HER2+ Breast Cancer
• Non-Small Cell Lung Cancer
• ER/PR Positive Breast Cancer
• HER2- Breast Cancer
• HER2-positive Breast Cancer
• HER2-negative Breast Cancer
• ER/PR(+), Her2(-) Breast Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

12 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

PMV Pharmaceuticals, Inc

Last updated on ClinicalTrials.gov

October 2, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites